CN102362860A - Budesonide and formoterol aerosol preparation taking hydro-fluoro-alkane as propellant - Google Patents
Budesonide and formoterol aerosol preparation taking hydro-fluoro-alkane as propellant Download PDFInfo
- Publication number
- CN102362860A CN102362860A CN2011103309507A CN201110330950A CN102362860A CN 102362860 A CN102362860 A CN 102362860A CN 2011103309507 A CN2011103309507 A CN 2011103309507A CN 201110330950 A CN201110330950 A CN 201110330950A CN 102362860 A CN102362860 A CN 102362860A
- Authority
- CN
- China
- Prior art keywords
- aerosol
- budesonide
- propellant
- formoterol
- formoterol fumarate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a budesonide and formoterol aerosol preparation, comprising budesonide, fumaric acid formoterol or physiologically acceptable salt and solvate granular medicine, a hydro-fluoro-alkane propellant, optionally small quantity of surfactant and optionally small quantity of cosolvent with polarity higher than the polarity of propellant. Experimental result shows that the aerosol preparation provided by the invention is a medical aerosol preparation with good stability.
Description
Technical field
The invention belongs to technical field of medicine, more particularly, relate to a kind of be propellant with the hydrofluoroalkane, contain the aerosol of budesonide and formoterol.
Background technology
Aerosol formulation is a kind of preparation through the respiratory tract administration approach.The basic order of respiratory tract administration technology is to make the medicine porous to pulmonary and be deposited on outer peripheral areas, has quick-acting, target spot administration and avoids advantages such as gastrointestinal tract first pass effect, side effect is little, dosage is little, has obtained internationally recognized.
For treatment asthma and chronic obstructive pulmonary disease, reach treatments such as those diseases that need the quick administration of general such as Cystic fibrosis, the respiratory tract administration approach not only has huge superiority, and is a kind of important therapeutic modality.But the preparation that is different from general medicine, the drug development that pulmonary absorbs has bigger technological challenge.Such as, the aerosol drug particle grain size distribution, the compatibility of drug particles and adjuvant and container all has high technical difficulty with the control of stability.The size that sucks microgranule is one of key issue that influences the aerosol formulation curative effect, and the suction granule of great majority above 5 microns will be trapped in the oral cavity or be stuck on the spout.Therefore, ideal inhalant particle size on average should be less than 3 microns, and 90% should be less than 5 microns.Yet, under the effect of cohesiveness, suck microgranule and trend towards caking, form big granule, microgranule is adsorbed in the packing of product easily simultaneously.
Therefore, for overcoming above-mentioned difficult point, in aerosol formulation, add surfactant and cosolvent (for example U.S. Pat 5225183, and US5439670 is to albuterol, beclometasone equimolecular) usually.Surfactant can be stablized aerosol formulation drug particles or increase-volume medicine, also can play lubricated aerosol container and valve function.The cosolvent dispersion solvent of doing commonly used improves the dissolubility between surfactant and the propellant.
It is to be noted; Formulation meets the chemical constitution that contained concrete component ratio in the clinical suitable aerosol formulation must depend on (comprising medicine, propellant, surfactant and cosolvent etc.) this special component in the whole preparation, physical characteristic and its compatibility each other.To the specific medication molecule; Through not adding or add specific surfactant and cosolvent, can improve concrete composition contained in the aerosol preparations (comprising medicine, propellant, surfactant and cosolvent etc.) its suitability each other and the quality and the stability of whole aerosol preparations.And the decision of concrete prescription must confirm whether said preparation can reach the quality standard that requires in the clinical practice through a large amount of experiments.
Summary of the invention
The inventor has invented a kind of fine budesonide formoterol aerosol astoundingly through a large amount of experiments, has successfully overcome some shortcomings of the prior art.
The purpose of this invention is to provide a kind of fine budesonide formoterol aerosol.
Another object of the present invention provides the method for preparing of above-mentioned budesonide and formoterol aerosol.
Specifically, the invention provides a kind of budesonide formoterol aerosol formulation, it comprises:
The granulated drug of budesonide and formoterol fumarate or its physiologically acceptable salt and solvate;
The hydrofluoroalkane propellant;
Basically do not contain polarity and be higher than the polar cosolvent of propellant;
And, randomly, contain surfactant.
In one embodiment of this invention, the invention provides a kind of budesonide formoterol aerosol formulation, it comprises:
The micronization granulated drug of budesonide and formoterol fumarate or its physiologically acceptable salt and solvate;
The hydrofluoroalkane propellant;
Basically do not contain polarity and be higher than the polar cosolvent of propellant;
And surfactant.
In one embodiment of this invention, the invention provides a kind of budesonide formoterol aerosol formulation, it comprises:
The micronization granulated drug of budesonide and formoterol fumarate or its physiologically acceptable salt and solvate;
The hydrofluoroalkane propellant;
Basically do not contain polarity and be higher than the polar cosolvent of propellant;
Do not contain surfactant.
In embodiments of the invention; The micronization granulated drug of budesonide and formoterol fumarate or its physiologically acceptable salt and solvate, wherein, the weight ratio of budesonide and formoterol fumarate is 50～300: 2～15; For example; 300: 8.3,160: 4.5, or 80: 4.5.
In embodiments of the invention, preferably, said granulated drug or micronization granulated drug account for the 0.01-5%W/W of said aerosol formulation, more preferably, are 0.01-3%W/W.
In embodiments of the invention, said granulated drug or micronization granulated drug, wherein, the diameter of the said granulated drug of 90%W/W is less than 5 μ m, and the diameter of the said granulated drug of 50%W/W is less than 3 μ m; Preferably, granulated drug is made by comminution by gas stream.
In embodiments of the invention, said hydrofluoroalkane propellant is preferably 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-seven fluorine n-propanes or its mixture.
In embodiments of the invention, the content of said hydrofluoroalkane propellant is the 93.5%-99.9%w/w of preparation.
In embodiments of the invention, said polarity is higher than the polar cosolvent of propellant, can be selected from propylene glycol or ethanol, more preferably is ethanol.
In embodiments of the invention; The said polarity that do not contain basically is higher than the polar cosolvent of propellant and is meant that not containing polarity is higher than the polar cosolvent of propellant, and the content that the polarity that perhaps contains is higher than the polar cosolvent of propellant is not more than 0.5%W/W (with respect to propellant).
In embodiments of the invention, said surfactant is Polyethylene Glycol or magnesium stearate or polyvinylpyrrolidone K25 (PVPK25).Here, described Polyethylene Glycol is PEG200～1800, can be PEG200, PEG300, PEG400, PEG1000; PEG1000 preferably.
In embodiments of the invention, the content of said surfactant is not more than the 1%W/W of preparation, more preferably, is not more than 0.5%W/W or is not more than 0.4%W/W, particularly preferably, is not more than 0.3%W/W.
In a kind of preferred embodiment of the present invention, the invention provides a kind of budesonide and formoterol aerosol, be to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate or its physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol formulation; 0.01-3%w/w preferably.
And hydrofluoroalkane propellant.
In a kind of preferred embodiment of the present invention, the invention provides a kind of budesonide and formoterol aerosol, be to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate or its physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol formulation; 0.01-3%w/w preferably.
The hydrofluoroalkane propellant;
And the surfactant that is not more than preparation 1%W/W.
In a kind of preferred embodiment of the present invention, the invention provides a kind of budesonide and formoterol aerosol, be to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate or its physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol formulation; 0.01-3%w/w preferably.
The hydrofluoroalkane propellant;
And the polarity that is not more than propellant 0.5%W/W is higher than the polar cosolvent of propellant.
In a kind of preferred embodiment of the present invention, the invention provides a kind of budesonide and formoterol aerosol, be to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate or its physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol formulation; 0.01-3%w/w preferably.
The hydrofluoroalkane propellant;
Be not more than the surfactant of preparation 1%W/W;
And the polarity that is not more than propellant 0.5%W/W is higher than the polar cosolvent of propellant.
In a kind of preferred embodiment of the present invention, the invention provides a kind of budesonide and formoterol aerosol, be to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate or its physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol formulation; 0.01-3%w/w preferably.
The hydrofluoroalkane propellant, said hydrofluoroalkane propellant is preferably 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-seven fluorine n-propanes or its mixture;
And the surfactant that is not more than preparation 1%W/W, said surfactant is Polyethylene Glycol or magnesium stearate or PVPK25.
In a kind of preferred embodiment of the present invention, the invention provides a kind of budesonide and formoterol aerosol, be to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate and physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol formulation; 0.01-3%w/w preferably.
The hydrofluoroalkane propellant, said hydrofluoroalkane propellant is preferably 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-seven fluorine n-propanes or its mixture;
And the polarity that is not more than propellant 0.5%W/W is higher than the polar cosolvent of propellant.
In a kind of preferred embodiment of the present invention, the invention provides a kind of budesonide and formoterol aerosol, be to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate and physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol formulation; 0.01-3%w/w preferably.
The hydrofluoroalkane propellant, said hydrofluoroalkane propellant is preferably 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-seven fluorine n-propanes or its mixture;
Be not more than the surfactant of preparation 1%W/W, said surfactant is Polyethylene Glycol or magnesium stearate or PVPK25.
And the polarity that is not more than propellant 0.5%W/W is higher than the polar cosolvent of propellant.
On the other hand, the invention provides the method for preparing of above-mentioned budesonide and formoterol aerosol.If aerosol formulation does not contain (or few) surfactant and cosolvent, medicine and propellant can first mix homogeneously, and be directly canned, promptly one goes on foot canned method.
The medicine that is used for aerosol formulation can be to be used to treat respiratory disorder (for example asthma and/or chronic obstructive pulmonary disease etc.) etc.; The short acting beta agonists trachea expanding agent is arranged; Like albuterol, terbutaline, isoproterenol etc.; It also can be the long acting beta agonists trachea expanding agent; For example salmaterol, formoterol also have steroid hormone such as beclometasone, budesonide, fluticasone and non-steroidal hormone cromoglicic acid etc., also comprise cholinolytic trachea expanding agent ipratropium bromide etc. simultaneously.
Though the said medicine molecule all can be used for treating respiratory disorder, no matter on structure, on physiologically acceptable salt or acid group or the base, these medicines are all inequality, and therefore, it reaches the aerosol formulation that meets clinical quality standard and forms also just obviously different.
On the basis of limited experiment, those skilled in the art is difficult to infer with the prescription of known aerosol system the aerosol formulation constituent of another kind of medicine.For example the beclometasone aerosol formulation generally need contain cosolvent such as ethanol.But the cosolvent composition of same ratio and inapplicable other medicines molecule such as salmaterol, FLUTICASONE PROPIONATE, the latter can not have under the situation of cosolvent usually, forms stable aerosol formulation.Even in similar molecule; Those skilled in the art also is difficult to infer whether certain drug molecule can form stable aerosol molecule under the situation that does not contain cosolvent and/or surfactant, the very difficult stable aerosol formulation that obtains to meet clinical quality standard easily through the simple replacement of drug molecule.
The characteristics of budesonide of the present invention and formoterol fumarate aerosol formulation are not contain basically under the situation of surfactant and cosolvent, and the granulated drug of budesonide and physiologically acceptable salt and solvate can form than contain cosolvent aerosol formulation more stable and that more optimize.
" be substantially devoid of surfactant " and be meant that preparation does not contain the surfactant of obvious amount, preferred, the content of its surfactant is not more than the 1.0%W/W of preparation.
" be substantially devoid of cosolvent " and be meant that preparation does not contain polarity and is higher than the polar liquid component of propellant, ethanol for example preferably is not more than the 0.5%W/W of propellant.
The particle diameter of said budesonide medicine and formoterol fumarate molecule requires all medicines should suck in the lung when taking this aerosol formulation basically, therefore, with less than 10 microns for well, 1-5 micron preferably.According to the characteristics of aerosol formulation self, the size that sucks microgranule is the key factor that influences the aerosol curative effect, and it will directly influence the aerosol formulation medicine maybe can breathe part at the deposition of pulmonary.Aerosol formulation can be breathed the ratio that part accounts for the medicine total amount; Being often referred to droplet distribution tests index---fine granular distributes; Be Fine Particle Fraction (write a Chinese character in simplified form FPF%, below herewith), generally require between 20-70%; Desirable between 30-60%, be the important indicator of investigating aerosol preparations.And the technological means of measuring FPF can be the binary collision technology, collides (ACI) and impinger of future generation (NGI) technology step by step, in conjunction with high performance liquid chromatograph (HPLC) analytical method.Budesonide formoterol aerosol formulation provided by the invention, through after collision is measured with HPLC step by step, it optimizes the FPF% value of writing out a prescription all more than 30%-40%, can stablize repetition.
The specific embodiment
By way of example and unrestricted following embodiment is used for explaining the present invention.
In description of the present invention, if no special instructions, described " % " is " % " of weight ratio.
Embodiment 1
Micronized budesonide and formoterol fumarate are weighed; Insert in the plastic coat vial or aluminium pot of clean dried; Seal bottle rapidly with metering valve, add hydrofluoroalkane propellant HFA 134a, then with ultrasonic 30 seconds of populated aerosol jar through metering valve.
Wherein, the gained aerosol contains the budesonide of 0.3%W/W, the formoterol fumarate of 0.025%W/W.The FPF% of this aerosol formulation budesonide reaches 44%, and the FPF% of formoterol fumarate is 38%.
By contrast, contain the aerosol of surfactant and cosolvent, the budesonide of 0.073%W/W adds 2.5% ethanol, and the FPF% of budesonide can only reach about 15%.
Embodiment 2
With micronized budesonide, formoterol fumarate and cetomacrogol 1000 are directly weighed in aluminium pot, seal bottle rapidly with metering valve, add hydrofluoroalkane propellant HFA134a through metering valve, then with ultrasonic 30 seconds of populated aerosol jar.
Wherein, the gained aerosol contains the budesonide of 0.3%W/W, the formoterol fumarate of 0.025%W/W and 0.3%PEG1000.The FPF% of this aerosol formulation budesonide reaches 47%, and the FPF% of formoterol fumarate reaches 55%.
Wherein, the gained aerosol contains the budesonide of 0.3%W/W, the formoterol fumarate of 0.025%W/W, 0.0224%PEG1000.The FPF% of this aerosol formulation budesonide reaches 44%, and the FPF% of formoterol fumarate reaches 59%.
Embodiment 3
With micronized budesonide, formoterol fumarate and magnesium stearate are directly weighed in aluminium pot, seal bottle rapidly with metering valve, add hydrofluoroalkane propellant HFA 134a through metering valve, then with ultrasonic 30 seconds of populated aerosol jar.
Wherein, the gained aerosol contains the budesonide of 0.3%W/W, the formoterol fumarate of 0.025%W/W and 0.1% magnesium stearate.The FPF% of this aerosol formulation budesonide reaches 35%, and the FPF% of formoterol fumarate reaches 38%.
Wherein, the gained aerosol contains the budesonide of 0.3%W/W, the formoterol fumarate of 0.025%W/W and 0.0028% magnesium stearate.The FPF% of this aerosol formulation budesonide reaches 39%, and the FPF% of formoterol fumarate reaches 38%.
Embodiment 1-3 proves, budesonide and formoterol fumarate aerosol preparations, and when not containing surfactant or containing low quantity of surfactant, its FPF% value all can reach more than 30%.
Embodiment 4
With micronized budesonide, formoterol fumarate and ethanol are directly weighed in aluminium pot, seal bottle rapidly with metering valve, add hydrofluoroalkane propellant HFA 134a through metering valve, then with ultrasonic 30 seconds of populated aerosol jar.
Wherein, the gained aerosol contains the budesonide of 0.3%W/W, the formoterol fumarate of 0.025%W/W and the ethanol of 0.25%W/W.The FPF% of this aerosol formulation budesonide reaches 32%, and the FPF% of formoterol fumarate reaches 35%.
Wherein, the gained aerosol contains the budesonide of 0.3%W/W, the formoterol fumarate of 0.025%W/W and the ethanol of 0.5%W/W.The FPF% of this aerosol formulation budesonide reaches 27%, and the FPF% of formoterol fumarate reaches 29%.
Embodiment 4 explanation: only containing under the situation that small amounts of co-solvents is not more than propellant 0.5%, its FPF% value is between 20-30%.
Embodiment 5
With micronized budesonide, formoterol fumarate and PEG1000, ethanol is directly weighed in aluminium pot, seals bottle rapidly with metering valve, adds hydrofluoroalkane propellant HFA134a through metering valve, then with ultrasonic 30 seconds of populated aerosol jar.
Wherein, the gained aerosol contains the budesonide of 0.3%W/W, the formoterol fumarate of 0.025%W/W and the PEG1000 of 0.0224%W/W, the ethanol of 0.5%W/W.The FPF% of this aerosol formulation budesonide reaches 26%, and the FPF% of formoterol fumarate reaches 52%.
Wherein, the gained aerosol contains the budesonide of 0.3%W/W, the formoterol fumarate of 0.025%W/W and the PEG1000 of 0.3%W/W, the ethanol of 0.5%W/W.The FPF% of this aerosol formulation budesonide reaches 27%, and the FPF% of formoterol fumarate reaches 48%.
Embodiment 5 explanations: when containing small amounts of co-solvents and low quantity of surfactant, its FPF% value of budesonide is between 20-30%, and the FPF% of formoterol fumarate is more than 40%.
Above-described, be according to preferred embodiment of the present invention, be not in order to limiting scope of the present invention, the above embodiment of the present invention can also be made various variations.Be that every simple, equivalence of doing according to the claims and the description of application of the present invention changes and modification, all fall into claim protection domain of the present invention.The present invention not technology contents of detailed description is those skilled in the art's a common practise.
Claims (10)
1. budesonide and formoterol aerosol, it comprises:
The micronization granulated drug of budesonide and formoterol fumarate or its physiologically acceptable salt and solvate;
The hydrofluoroalkane propellant;
Basically do not contain polarity and be higher than the polar cosolvent of propellant;
And, randomly, contain surfactant.
2. aerosol as claimed in claim 1, wherein, said micronization granulated drug accounts for the 0.01-5%W/W of said aerosol, preferably 0.01-3%w/w.
3. aerosol as claimed in claim 1, wherein, the diameter of the said granulated drug of 90%W/W is less than 5 μ m, and the diameter of the said granulated drug of 50%W/W is less than 3 μ m; Preferably granulated drug is made by comminution by gas stream.
4. aerosol as claimed in claim 1, wherein, said propellant is 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-seven fluorine n-propanes or its mixture.
5. budesonide and formoterol aerosol are to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate or its physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol; 0.01-3%w/w preferably;
And hydrofluoroalkane propellant.
6. budesonide and formoterol aerosol are to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate or its physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol; 0.01-3%w/w preferably;
The hydrofluoroalkane propellant;
And the surfactant that is not more than preparation 1%W/W.
7. budesonide and formoterol aerosol are to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate or its physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol; 0.01-3%w/w preferably;
The hydrofluoroalkane propellant;
And the polarity that is not more than propellant 0.5%W/W is higher than the polar cosolvent of propellant.
8. budesonide and formoterol aerosol are to be prepared from following component:
Account for budesonide and the micronization granulated drug of formoterol fumarate or its physiologically acceptable salt and solvate of the 0.01-5%W/W of said aerosol; 0.01-3%w/w preferably;
The hydrofluoroalkane propellant;
Be not more than the surfactant of preparation 1%W/W;
And the polarity that is not more than propellant 0.5%W/W is higher than the polar cosolvent aerosol of propellant.
9. be used for the aerosol container like each described aerosol of claim 1-8, it comprises the container of the vapour pressure that can bear said aerosol formulation, and this container has the metering valve spout, and the diameter of this spout is 0.2-0.6mm, is preferably 0.3-0.5mm.
10. aerosol container as claimed in claim 9, wherein, the inner surface of said container has coating or does not have coating, optimization be fluorine coating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103309507A CN102362860A (en) | 2011-10-27 | 2011-10-27 | Budesonide and formoterol aerosol preparation taking hydro-fluoro-alkane as propellant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103309507A CN102362860A (en) | 2011-10-27 | 2011-10-27 | Budesonide and formoterol aerosol preparation taking hydro-fluoro-alkane as propellant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102362860A true CN102362860A (en) | 2012-02-29 |
Family
ID=45689477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103309507A Pending CN102362860A (en) | 2011-10-27 | 2011-10-27 | Budesonide and formoterol aerosol preparation taking hydro-fluoro-alkane as propellant |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102362860A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2554092A (en) * | 2016-09-19 | 2018-03-28 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| CN109464429A (en) * | 2018-12-13 | 2019-03-15 | 上海方予健康医药科技有限公司 | A kind of suction pressure quantitative aerosol pharmaceutical composition and preparation method thereof |
| AU2016364650B2 (en) * | 2015-12-04 | 2019-04-04 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| CN1271287A (en) * | 1997-09-19 | 2000-10-25 | 阿斯特拉公司 | New use of budesonide and formoterol |
| CN1499958A (en) * | 2001-03-30 | 2004-05-26 | Medical aerosol formulations |
-
2011
- 2011-10-27 CN CN2011103309507A patent/CN102362860A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1271287A (en) * | 1997-09-19 | 2000-10-25 | 阿斯特拉公司 | New use of budesonide and formoterol |
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| CN1499958A (en) * | 2001-03-30 | 2004-05-26 | Medical aerosol formulations |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016364650B2 (en) * | 2015-12-04 | 2019-04-04 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| AU2019202875B2 (en) * | 2015-12-04 | 2020-03-12 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| AU2019202874B2 (en) * | 2015-12-04 | 2020-03-12 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| AU2019202874C1 (en) * | 2015-12-04 | 2020-08-06 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| US11559505B2 (en) | 2015-12-04 | 2023-01-24 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| US11559506B2 (en) | 2015-12-04 | 2023-01-24 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| US11559507B2 (en) | 2015-12-04 | 2023-01-24 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| GB2554092A (en) * | 2016-09-19 | 2018-03-28 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| CN109464429A (en) * | 2018-12-13 | 2019-03-15 | 上海方予健康医药科技有限公司 | A kind of suction pressure quantitative aerosol pharmaceutical composition and preparation method thereof |
| CN109464429B (en) * | 2018-12-13 | 2021-04-27 | 上海方予健康医药科技有限公司 | Inhalation pressure quantitative aerosol pharmaceutical composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10258568B2 (en) | Pharmaceutical compositions | |
| TWI660747B (en) | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination | |
| JP6534397B2 (en) | Stable pressurized aerosol solution composition of a combination of glycopyrronium bromide and formoterol | |
| JP6899824B2 (en) | Pharmaceutical composition | |
| CA3037107C (en) | Stable pharmaceutical compositions comprising salmeterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis) | |
| CN101502500A (en) | Pressurised metered dose inhalers containing solutions of beta-2 agonists | |
| CA3036628C (en) | Pharmaceutical compositions comprising tiotropium bromide monohydrate and 1,1-difluoroethane | |
| CN101198313A (en) | Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation | |
| US20100095963A1 (en) | Pharmaceutical compositions | |
| BR112014008602B1 (en) | Pharmaceutical composition, sealed container, metered dose inhaler, and method for making a pharmaceutical composition | |
| CN108289842A (en) | Pharmaceutical composition | |
| CN102362860A (en) | Budesonide and formoterol aerosol preparation taking hydro-fluoro-alkane as propellant | |
| CN102362859A (en) | Budesonide aerosol preparation using hydrofluoroalkane as propellent | |
| US20130104881A1 (en) | Stabilized Metered Dose Inhaler | |
| AU2012300082B2 (en) | Method for preparing metered dose sprayed inhaler for treating respiratory disease | |
| EP3909582A1 (en) | Pharmaceutical composition comprising indacaterol | |
| GB2554091A (en) | Pharmaceutical composition | |
| CN103655473A (en) | Budesonide aerosol preparation with hydrofluoroalkane used as propellant | |
| CN102366406B (en) | Salmeterol/fluticasone aerosol preparation with hydrofluoroalkane as propellent | |
| CN103520106A (en) | Salbutamol sulphate inhalation aerosol and preparation method thereof | |
| CN102379846B (en) | Fluticasone propionate aerosol preparation with hydrofluoroalkane and polyethylene glycol as auxiliary materials | |
| CN102366405A (en) | Fluticasone propionate aerosol preparation with hydrofluoroalkane as propellant | |
| US9241904B1 (en) | Method for preparing metered dose sprayed inhaler for treating respiratory disease | |
| CN100457087C (en) | Stable pharmaceutical solution formulation for pressurized metered dose inhalers | |
| WO2024157282A1 (en) | Pharmaceutical compositions of green propellant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU CF PHARMACEUTICAL TECHNOLOGY INC. Free format text: FORMER OWNER: CF PHARMACEUTICAL TECHNOLOGY INC. Effective date: 20130426 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20130426 Address after: Jinxi road Binhu District 214125 Jiangsu city of Wuxi province No. 100 Applicant after: Jiangsu Changfeng Pharmaceutical Co., Ltd. Address before: Jinxi road Binhu District 214125 Jiangsu city of Wuxi province No. 99 Jiang Technology Park Room 203 Applicant before: Jiangyin Changfeng Medical Technology Co.,Ltd. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120229 |